Document is current
Any future updates will be listed below
-
Authors
Lim, Jeong-Hoon
Seo, Yu Jin
Pecoits-Filho, Roberto
Bieber, Brian
Perl, Jeffrey
Johnson, David W.
Jung, Hee-Yeon
Choi, Ji-Young
Cho, Jang-Hee
Kim, Chan-Duck
Oh, Kook-Hwan
Park, Sun-Hee
Kim, Yong-Lim
,
Kim, Yong-Lim
Park, Sun-Hee
Oh, Kook-Hwan
Lee, Young-Ki
Yoon, Se-Hee
Kwon, Young-Joo
Song, Sang Heon
Park, Cheol Whee
Han, Seung Hyeok
Lee, Min-Jeong
Han, Byoung Geun
Ryu, Jung-Hwa
Song, Joon Ho
Kim, Nam-Ho
Shin, Byung Chul
Lee, Eun Young
Lee, Chung Sik
Kim, Yang Wook
Sung, Su-Ah
Kim, Joong Kyung
Chang, Tae Ik
Lee, Jong-Hak
Yoon, Jong-Woo
-
Funding
Funding for this research was provided by:
Korea Health Industry Development Institute (HR22C1832)
Baxter, Korea
Fresenius Medical Care, Korea
Kyowa Hako Kirin, Korea
Chongkeundang, Korea
- License Information
-
More Information
Article History
Received: 13 March 2024
Accepted: 24 September 2024
First Online: 3 October 2024
Declarations
:
: David Johnson has received consultancy fees, research grants, speaker’s honoraria and travel sponsorships from Baxter Healthcare and Fresenius Medical Care, consultancy fees from Astra Zeneca, Bayer, and AWAK, speaker’s honoraria from ONO and Boehringer Ingelheim & Lilly, and travel sponsorships from Ono and Amgen. He is a current recipient of an Australian National Health and Medical Research Council Leadership Investigator Grant. Jeffrey Perl reports support from AHRQ and Arbor Research Collaborative for Health. He has received consulting fees from Astra Zeneca, Baxter Healthcare, GSK, Otsuka, Amgen, Pfizer, and Bayer; honoraria from Baxter Healthcare, FMC, DaVita Healthcare, Innovative Renal Care, AMGEN, and US Renal Care; and owns stock in LiberDi. The remaining authors declare no conflict of interest.
